Sarepta's Duchenne gene therapy misses main goal in study
03/11/2025 21:22
Nov 3 (Reuters) - Sarepta SRPT.O said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not meet the main goal. (Reporting by Kamal Choudhury in Bengaluru; Editing by Alan Barona) ((Kamal.Choudhury@thomsonreuters.com))
Recent news on Sarepta Therapeutics
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Sarepta, Dyne fall after Novartis muscle disorder trial failure